摘要
目的 :评价美托洛尔治疗缺血性心脏病心力衰竭的临床疗效。方法 :5 2例缺血性心脏病心力衰竭患者接受常规治疗 (硝酸酯、洋地黄、利尿剂、血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂 )病情稳定后 ,随机分为两组 :美托洛尔组 2 6例 ,常规对照组 2 6例。从小剂量开始 (美托洛尔组 ,初始剂量 6 2 5mg/次 ,2次 /d) ,缓慢递增。评估治疗前后缺血性心脏病心力衰竭患者心功能分级 ,并做超声心动图测定左室功能改变 ,摄心脏正位片测定心胸比值。结果 :治疗 6个月后 ,美托洛尔能够明显改善缺血性心脏病心力衰竭患者的心脏功能 ,使左室射血分数 (LVEF)明显增加 ,左心房内径 (LAD)、左心室收缩末期内径 (LVSD)、左心室舒张末期内径 (LVDD)均明显减小 ,心胸比值降低。结论 :美托洛尔能够明显改善缺血性心脏病心力衰竭患者的心功能 ,逆转左室重构。
Objective:To evaluate the clinical curative effect of Metoprolo on heart failure in ischemic heart disease.Method:52 cases of heart failure were treated with routine therapy (Nitarte,Digitalis,Diuretic,Angiotensin invertase inhibitor or Angiotensin recep tor antagonist).After their conditions were stable,they were randomly divided into two groups:the Metbprolol group (26 cases) and placebo group (26 ones).The dosage was increased gradually(For the Metoprolol group,the initial dosage is 6.25mg once,twice daily).The levels of cardiac function before and after treatment were evaluated The changes of left ventricular function were measured by echocardiography.the cardiothoracic ratio was cletermined in heart orthophoria.Result:After six months,the cardiac functions in Metoprolol group improved obviously,with LVEF increasing obviously,LAD,LVSD,LVDD and the cardiothoracic ratio decreasing obviously.Conclusion:Metopolol can remarkably improve the cardiac function of patients with heart failure in ischemic heart disease.
出处
《内蒙古医学杂志》
2004年第6期407-409,共3页
Inner Mongolia Medical Journal
